Spero Therapeutics (SPRO) Debt to Equity (2016 - 2025)
Spero Therapeutics' Debt to Equity history spans 10 years, with the latest figure at $0.0 for Q4 2025.
- For Q4 2025, Debt to Equity changed N/A year-over-year to $0.0; the TTM value through Dec 2025 reached $0.0, changed N/A, while the annual FY2025 figure was $0.0, N/A changed from the prior year.
- Debt to Equity reached $0.0 in Q4 2025 per SPRO's latest filing, up from $0.0 in the prior quarter.
- In the past five years, Debt to Equity ranged from a high of $0.02 in Q1 2022 to a low of $0.0 in Q3 2024.
- Average Debt to Equity over 5 years is $0.0, with a median of $0.0 recorded in 2021.
- Peak YoY movement for Debt to Equity: skyrocketed 1171.64% in 2022, then crashed 92.71% in 2023.
- A 5-year view of Debt to Equity shows it stood at $0.0 in 2021, then decreased by 19.12% to $0.0 in 2022, then crashed by 35.62% to $0.0 in 2023, then crashed by 75.62% to $0.0 in 2024, then skyrocketed by 676.93% to $0.0 in 2025.
- Per Business Quant, the three most recent readings for SPRO's Debt to Equity are $0.0 (Q4 2025), $0.0 (Q3 2024), and $0.0 (Q2 2024).